pyridoxineWhat was measured
Measured, with no finding
2,534 endpoints
Show what was measuredHide what was measured
visual and myoclonic seizures after vitamin B6 withdrawal
increases, n = 1
At the age of 12 years 1 month, 2 months after withdrawal of vitamin B6, visual seizures began to occur frequently
PMID 10210253 · one of two readings recorded this
RBC folate
decreases
The mean RBC folate concentration for patients taking diuretics (281.01 +/- 17.56 ng/mL) was significantly lower than the mean RBC folate concentration for patients not taking diuretics (430.85 +/- 28.58 ng/mL)
PMID 10498160 · one of two readings recorded this
serum homocysteine
increases
The mean serum homocysteine concentration for patients taking diuretics (17.87 +/- 1.72 micromol/L) was significantly higher than the mean serum homocysteine concentration for patients not taking diuretics (10.31 +/- 0.99 micromol/L)
PMID 10498160 · one of two readings recorded this
serum vitamin B6 and vitamin B12
no effect
Serum vitamin B6 and vitamin B12 concentrations were not significantly different between the two groups
PMID 10498160 · one of two readings recorded this
serum vitamin B6 concentration in hypertensive patients on long-term diuretics versus not; diuretic is the exposure
no effect, serum vitamin B6 not significantly different between diuretic and non-diuretic groups
Not recorded as a finding: the compound is what was measured, not what was given
Serum vitamin B6 and vitamin B12 concentrations were not significantly different between the two groups.
PMID 10498160 · one of two readings recorded this
serum vitamin B6 concentration in hypertensive patients on long-term diuretics versus not on diuretics
no effect
Not recorded as a finding: the compound is what was measured, not what was given
Serum vitamin B6 and vitamin B12 concentrations were not significantly different between the two groups.
PMID 10498160 · one of two readings recorded this
incidence of dental decay in pregnant women, pyridoxine capsules or lozenges versus control
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Pyridoxine supplementation either as oral capsules (odds ratio 0.63, 95% confidence interval 0. 41 to 0.95) or lozenges (odds ratio 0.33, 95% confidence interval 0. 22-0.51) was associated with decreased incidence of dental decay in pregnant women.
PMID 10796172 · one of two readings recorded this
incidence of dental decay in pregnant women
decreases, n = 371
or lozenges (odds ratio 0.33, 95% confidence interval 0. 22-0.51)
PMID 10796172 · one of two readings recorded this
incidence of dental decay in pregnant women
decreases, n = 371
Pyridoxine supplementation either as oral capsules (odds ratio 0.63, 95% confidence interval 0. 41 to 0.95)
PMID 10796172 · one of two readings recorded this
peripheral polyneuropathy symptom score (the authors' PPN symptom score) and predialysis serum pyridoxal-5'-phosphate in haemodialysis patients
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Nonetheless, it was demonstrated that supplementation with vitamin B(6) for 4 weeks significantly increased the predialysis level of P5P and dramatically attenuated PPN symptoms compared with initial symptoms.
PMID 10978399 · one of two readings recorded this
PPN symptom score
no effect
No improvement was observed in response to vitamin B(12) supplementation
PMID 10978399 · one of two readings recorded this
PPN symptom score
decreases
supplementation with vitamin B(6) for 4 weeks significantly increased the predialysis level of P5P and dramatically attenuated PPN symptoms compared with initial symptoms
PMID 10978399 · one of two readings recorded this
predialysis serum P5P after supplementation
increases
supplementation with vitamin B(6) for 4 weeks significantly increased the predialysis level of P5P
PMID 10978399 · one of two readings recorded this
predialysis serum P5P, PPN vs non-PPN patients
no effect
predialysis serum P5P levels of HD patients with PPN were not significantly lower than those of matched HD patients without PPN
PMID 10978399 · one of two readings recorded this
PANSS scores (mental state)
no effect, n = 15
PANSS scores revealed no differences between vitamin B6- and placebo-treated patients in amelioration of their mental state
PMID 11838627 · one of two readings recorded this
psychotic symptoms in schizophrenia, Positive and Negative Syndrome Scale (PANSS)
no effect, no differences in PANSS between vitamin B6 and placebo
Not recorded as a finding: this platform holds no node for the endpoint
PANSS scores revealed no differences between vitamin B6- and placebo-treated patients in amelioration of their mental state.
PMID 11838627 · one of two readings recorded this
psychotic symptoms on the Positive and Negative Syndrome Scale (PANSS) in schizophrenia and schizoaffective patients
no effect
Not recorded as a finding: this platform holds no node for the endpoint
PANSS scores revealed no differences between vitamin B6- and placebo-treated patients in amelioration of their mental state.
PMID 11838627 · one of two readings recorded this
erythrocyte alanine and aspartate aminotransaminase activity coefficients
no effect
Erythrocyte alanine aminotransaminase activity coefficient and EAST-AC did not change significantly
PMID 12001008 · one of two readings recorded this
mean vitamin B6 intake over study
Patients had an adequate mean vitamin B6 intake (16.26+/-19.39 mg) during the 14 day study
PMID 12001008 · one of two readings recorded this
plasma PLP and PL concentrations
decreases, p = 0.05
plasma PLP and PL concentrations significantly decreased at the 14th day after admission (P<0.05)
PMID 12001008 · one of two readings recorded this
relationship of vitamin B6 intake and status indicators (plasma PLP, PL, urinary 4-PA, EALT-AC, EAST-AC) with APACHE II score, length of ICU and hospital stay and ventilation dependency in ventilated critically ill patients
no effect
Not recorded as a finding: no estimate is reported anywhere
No significant relationships were found between APACHE II scores and clinical outcomes (the length of ICU and hospital stay, the length of ventilation dependency) of patients, vitamin B6 intake or status indicators.
PMID 12001008 · one of two readings recorded this
urinary 4-pyridoxic acid
increases, p = 0.001
Urinary 4-PA significantly increased at the 14th day (P<0.001)
PMID 12001008 · one of two readings recorded this
vitamin B6 intake, day 14 vs day 1
increases, p = 0.001
Mean vitamin B6 intake was significantly higher on day 14 than on day 1 (P<0.001)
PMID 12001008 · one of two readings recorded this
PLP association with reticulocyte count
decreases
PLP concentration was associated positively with weight, body mass index, and arm circumference -scores and negatively with reticulocyte count
PMID 12218594 · one of two readings recorded this
proportion with PLP below deficiency criterion
Seventy-seven percent had a PLP concentration below the deficiency criterion (20 nmol/L) suggested by the Dietary Reference Intakes (1998)
PMID 12218594 · one of two readings recorded this
serum pyridoxal 5-phosphate (PLP) concentration
The PLP concentration of subjects with SCD-SS was 15.6 +/- 15.2 nmol/L
PMID 12218594 · one of two readings recorded this
urinary 4-pyridoxic acid
decreases
Urinary 4-PA was lower in children with SCD-SS versus controls, although 4-PA/creatinine values did not differ between groups
PMID 12218594 · one of two readings recorded this
vitamin B6 status in children with sickle cell disease-SS, serum pyridoxal 5-phosphate and urinary 4-pyridoxic acid
Not recorded as a finding: the compound is what was measured, not what was given
Seventy-seven percent had a PLP concentration below the deficiency criterion (20 nmol/L) suggested by the Dietary Reference Intakes (1998).
PMID 12218594 · one of two readings recorded this
plasma 4-PA increase after vitamin B6
increases
Three days after the start of treatment, the increases in concentration were approximately 10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively
PMID 12507972 · one of two readings recorded this
plasma 4-PA intraindividual variation
During the 84-day study period, the intraindividual variation (CV) in patients not treated with vitamin B(6) (groups B and D) was 45% for PLP and 67% for 4-PA
PMID 12507972 · one of two readings recorded this
plasma B6 vitamer concentrations (pyridoxal 5'-phosphate, pyridoxal, 4-pyridoxic acid) before and after oral vitamin B6
increases
Not recorded as a finding: this platform holds no node for the endpoint
Three days after the start of treatment, the increases in concentration were approximately 10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively.
PMID 12507972 · one of two readings recorded this
plasma B6 vitamers, later time points
no effect
No significant additional increase was observed at the later time points
PMID 12507972 · one of two readings recorded this
plasma PL increase after vitamin B6
increases
Three days after the start of treatment, the increases in concentration were approximately 10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively
PMID 12507972 · one of two readings recorded this
plasma PLP increase after vitamin B6
increases
Three days after the start of treatment, the increases in concentration were approximately 10-, 50-, and 100-fold for PLP, 4-PA, and PL, respectively
PMID 12507972 · one of two readings recorded this
plasma PLP intraindividual variation
During the 84-day study period, the intraindividual variation (CV) in patients not treated with vitamin B(6) (groups B and D) was 45% for PLP and 67% for 4-PA
PMID 12507972 · one of two readings recorded this
breast cancer risk by plasma vitamin B6 (pyridoxal phosphate) quintile, nested case-control
RR 0.70, 95% CI 0.48 to 1.02 highest vs lowest quintile
Not recorded as a finding: a direction is stated and the estimate does not support it
The multivariable RR comparing women in the highest quintile of plasma vitamin B(6) levels with those in the lowest quintile was 0.70 (95% CI = 0.48 to 1.02; P(trend) =.09).
PMID 12618502 · one of two readings recorded this
breast cancer risk by plasma vitamin B6 quintile, nested case-control, Nurses' Health Study
decreases, multivariable RR 0.70, 95% CI = 0.48 to 1.02; P(trend) = .09, p = 0.09
Not recorded as a finding: a direction is stated and the estimate does not support it
The multivariable RR comparing women in the highest quintile of plasma vitamin B(6) levels with those in the lowest quintile was 0.70 (95% CI = 0.48 to 1.02; P(trend) =.09).
PMID 12618502 · one of two readings recorded this
breast cancer risk
decreases, p = 0.06
The multivariable RR comparing women in the highest quintile of plasma folate with those in the lowest was 0.73 (95% confidence interval [CI] = 0.50 to 1.07; P(trend) =.06)
PMID 12618502 · one of two readings recorded this
breast cancer risk
no effect
Plasma homocysteine was not associated with breast cancer risk
PMID 12618502 · one of two readings recorded this
breast cancer risk
decreases, p = 0.09
The multivariable RR comparing women in the highest quintile of plasma vitamin B(6) levels with those in the lowest quintile was 0.70 (95% CI = 0.48 to 1.02; P(trend) =.09)
PMID 12618502 · one of two readings recorded this
breast cancer risk
decreases
among women consuming at least 15 g/day (i.e., approximately 1 drink/day) of alcohol (multivariable RR = 0.11, 95% CI = 0.02 to 0.59 for highest versus lowest quintile)
PMID 12618502 · one of two readings recorded this
breast cancer risk
decreases
in contrast with that of women consuming less than 15 g/day (multivariable RR = 0.72, 95% CI = 0.49 to 1.05)
PMID 12618502 · one of two readings recorded this
breast cancer risk
decreases
Plasma vitamin B(12) levels were inversely associated with breast cancer risk among premenopausal women (multivariable RR = 0.36, 95% CI = 0.15 to 0.86 for highest versus lowest quintile)
PMID 12618502 · one of two readings recorded this
ischemic stroke or transient ischemic attack case-control status by low plasma pyridoxal 5'-phosphate; endogenous PLP level, nobody dosed
increases, adjusted OR 4.6, 95% CI 1.4 to 15.1 for low PLP
Not recorded as a finding: another reason, stated per paper
After stroke risk factors were controlled for, a strong independent association was present between stroke/TIA and low PLP (adjusted odds ratio [OR], 4.6; 95% CI, 1.4 to 15.1; P<0.001) but not elevated tHcy (OR, 0.92; 95% CI, 0.4 to 2.1).
PMID 12738890 · one of two readings recorded this
ischemic stroke/TIA case status by fasting plasma pyridoxal 5'-phosphate, case-control
increases, low PLP adjusted OR 4.6, 95% CI 1.4 to 15.1
Not recorded as a finding: another reason, stated per paper
After stroke risk factors were controlled for, a strong independent association was present between stroke/TIA and low PLP (adjusted odds ratio [OR], 4.6; 95% CI, 1.4 to 15.1; P<0.001) but not elevated tHcy (OR, 0.92; 95% CI, 0.4 to 2.1).
PMID 12738890 · one of two readings recorded this
mean plasma pyridoxal 5'-phosphate (PLP)
decreases, p = 0.0001
Mean PLP was significantly lower in cases than controls (39.97 versus 84.1 nmol/L, P<0.0001)
PMID 12738890 · one of two readings recorded this
stroke/TIA risk associated with elevated tHcy
no effect
but not elevated tHcy (OR, 0.92; 95% CI, 0.4 to 2.1)
PMID 12738890 · one of two readings recorded this
stroke/TIA risk associated with low PLP
increases, p = 0.001
a strong independent association was present between stroke/TIA and low PLP (adjusted odds ratio [OR], 4.6; 95% CI, 1.4 to 15.1; P<0.001)
PMID 12738890 · one of two readings recorded this
association of tHcy with education, CDR, MMSE, blood lipids, albumin or ApoE genotype
no effect, p = 0.15
tHcy levels were not related in AD patients or controls to education, CDR, MMSE, blood lipids, albumin or ApoE genotype (p>0.15)
PMID 12766793 · one of two readings recorded this
correlation of plasma tHcy with triglyceride levels
decreases, p = 0.023
There was a negative correlation between plasma tHcy and triglyceride levels in AD patients (p=0.023), but not in controls
PMID 12766793 · one of two readings recorded this
dietary folate intake after age 60
decreases, p = 0.001
AD patients consumed significantly less dietary vitamin B6 (p=0.05) and folate (p=0.001) after age 60 than controls
PMID 12766793 · one of two readings recorded this
dietary vitamin B6 intake after age 60 in Alzheimer's disease patients versus matched controls, by questionnaire
decreases, AD patients consumed less dietary vitamin B6 than controls, p=0.05, p = 0.05
Not recorded as a finding: the compound is what was measured, not what was given
AD patients consumed significantly less dietary vitamin B6 (p=0.05) and folate (p=0.001) after age 60 than controls.
PMID 12766793 · one of two readings recorded this
dietary vitamin B6 intake after age 60
decreases, p = 0.05
AD patients consumed significantly less dietary vitamin B6 (p=0.05) and folate (p=0.001) after age 60 than controls
PMID 12766793 · one of two readings recorded this
estimated daily dietary vitamin B6 intake after age 60 in Alzheimer's disease patients versus matched controls, from a food frequency questionnaire
decreases, p = 0.05
Not recorded as a finding: the compound is what was measured, not what was given
AD patients consumed significantly less dietary vitamin B6 (p=0.05) and folate (p=0.001) after age 60 than controls.
PMID 12766793 · one of two readings recorded this
plasma total homocysteine
no effect, p = 0.25
tHcy did not differ significantly between controls (11.5 +/- 3.7 mmol/L) and AD patients (12.3 +/- 4.3 mmol/L)(p=0.25)
PMID 12766793 · one of two readings recorded this
cognition and mood
no effect
No statistically significant differences between treatment and placebo were found in their effects on cognition or mood
PMID 14584010 · one of two readings recorded this
cognition or mood in healthy older people, vitamin B6 versus placebo (instrument not named in the abstract)
no effect
Not recorded as a finding: this platform holds no node for the endpoint
No statistically significant differences between treatment and placebo were found in their effects on cognition or mood.
PMID 14584010 · one of two readings recorded this
erythrocyte aspartate aminotransferase activity (vitamin B6 status)
increases, p = 0.00001
erythrocyte enzyme asparate aminotransferase (WMD 0.43, 95%CI 0.30 to 0.56, P<0.00001)
PMID 14584010 · one of two readings recorded this
mood and cognition
no effect
No statistically significant benefits from vitamin B6 on mood or cognition were observed
PMID 14584010 · one of two readings recorded this
plasma pyridoxal-5'-phosphate (blood vitamin B6 activity)
increases, p = 0.00001
increased blood vitamin B6 activity as assessed as by plasma pyridoxal-5'-phosphate (WMD 238, 95%CI 211.58 to 264.42, P<0.00001)
PMID 14584010 · one of two readings recorded this
electrophoretic mobility of peripheral blood lymphocytes and cellular immunity
increases
A favourable effect was found of daily oral administration of 50 mg pyridoxine on electrophoretic mobility of peripheral blood lymphocytes and cellular immunity
PMID 1459821 · one of two readings recorded this
erythrocyte vitamin B6
no effect
Haemodialysis and charcoal haemoperfusion have led to non-significant decrease of erythrocyte vitamin B6
PMID 1459821 · one of two readings recorded this
prevention of vitamin B6 deficiency
decreases
long-term daily oral supplementation of 6 mg vitamin B6 was sufficient for prevention of vitamin B6 deficiency in chronic renal failure
PMID 1459821 · one of two readings recorded this
nausea score change, ginger vs vitamin B6
no effect, p = 0.136
The mean score change after treatment with ginger was 1.4 (2.21), less than with vitamin B6, which was 2.0 (2.19) but with no statistically significant difference (95% CI -1.4 to 0.2, p = 0.136)
PMID 14649969 · one of two readings recorded this
nausea score on visual analogue scale and number of vomiting episodes in nausea and vomiting of pregnancy
no effect, no significant difference between ginger and vitamin B6 in nausea score change (95% CI -1.4 to 0.2), p = 0.136
Not recorded as a finding: the comparison was against another active treatment
The mean score change after treatment with ginger was 1.4 (2.21), less than with vitamin B6, which was 2.0 (2.19) but with no statistically significant difference (95% CI -1.4 to 0.2, p = 0.136).
PMID 14649969 · one of two readings recorded this
nausea score (VAS), ginger arm
decreases, p = 0.001
The ginger and vitamin B6 significantly reduced the nausea scores from 5.0 (SD, 1.99) to 3.6 (SD, 2.48) and 5.3 (SD, 2.08) to 3.3 (SD, 2.07) respectively, with p < 0.001
PMID 14649969 · one of two readings recorded this
nausea score (VAS), vitamin B6 arm
decreases, p = 0.001
The ginger and vitamin B6 significantly reduced the nausea scores from 5.0 (SD, 1.99) to 3.6 (SD, 2.48) and 5.3 (SD, 2.08) to 3.3 (SD, 2.07) respectively, with p < 0.001
PMID 14649969 · one of two readings recorded this
vomiting episodes change, ginger vs vitamin B6
no effect, p = 0.498
The mean number change after treatment with ginger was 0.7 (2.18), more than with vitamin B6, which was 0.5 (1.44) but with no statistically significant difference, (p = 0.498)
PMID 14649969 · one of two readings recorded this
vomiting episodes in previous 24 hours, ginger arm
decreases, p = 0.01
The ginger and vitamin B6 also significantly reduced the number of vomiting episodes from 1.9 (2.06) to 1.2 (1.75) and 1.7 (1.81) to 1.2 (1.50) respectively, with p < 0.01
PMID 14649969 · one of two readings recorded this
vomiting episodes in previous 24 hours, vitamin B6 arm
decreases, p = 0.01
The ginger and vitamin B6 also significantly reduced the number of vomiting episodes from 1.9 (2.06) to 1.2 (1.75) and 1.7 (1.81) to 1.2 (1.50) respectively, with p < 0.01
PMID 14649969 · one of two readings recorded this
incident hemorrhagic stroke
no effect
intake of folate was associated with a significantly lower risk of ischemic but not hemorrhagic stroke
PMID 14671243 · one of two readings recorded this
incident ischemic stroke
decreases, p = 0.05
The multivariate relative risk of ischemic stroke was 0.71 (95% CI, 0.52 to 0.96; P for trend=0.05) for men in the highest quintile of intake compared with those who in the lowest quintile
PMID 14671243 · one of two readings recorded this
incident ischemic stroke
decreases
Intake of vitamin B12, but not B6, was also inversely associated with risk of ischemic stroke
PMID 14671243 · one of two readings recorded this
incident ischemic stroke
no effect
Intake of vitamin B12, but not B6, was also inversely associated with risk of ischemic stroke
PMID 14671243 · one of two readings recorded this
daily folate intake
decreases
Daily folate intake was significantly lower in case subjects (mean, 288; 95% confidence interval [CI], 266-309 microg) than in control subjects (324; 95% CI, 313-335 microg)
PMID 14981440 · one of two readings recorded this
daily vitamin B6 intake
decreases
Daily vitamin B6 intake was also lower in case subjects (2.05; 95% CI, 1.92-2.19 mg versus 2.26; 95% CI, 2.19-2.33 mg)
PMID 14981440 · one of two readings recorded this
peripheral arterial occlusive disease, ankle-brachial pressure index < 0.9, by dietary vitamin B6 intake
decreases
Not recorded as a finding: this platform holds no node for the endpoint
A similar increase in daily vitamin B6 intake decreased the risk of PAOD by 29%.
PMID 14981440 · one of two readings recorded this
peripheral arterial occlusive disease defined as ankle-brachial pressure index < 0.9, by daily dietary vitamin B6 intake (EPIC food frequency questionnaire)
decreases
Not recorded as a finding: this platform holds no node for the endpoint
A similar increase in daily vitamin B6 intake decreased the risk of PAOD by 29%.
PMID 14981440 · one of two readings recorded this
prevalence of peripheral arterial occlusive disease (ABPI < 0.9)
PAOD, defined as an ankle-brachial pressure index (ABPI) < 0.9, was present in 86 (22%) of subjects
PMID 14981440 · one of two readings recorded this
risk of PAOD per 1 standard deviation increase in folate intake
decreases
This model suggests that increasing daily folate intake by 1 standard deviation decreased the risk of PAOD by 46%
PMID 14981440 · one of two readings recorded this
risk of PAOD per 1 standard deviation increase in vitamin B6 intake
decreases
A similar increase in daily vitamin B6 intake decreased the risk of PAOD by 29%
PMID 14981440 · one of two readings recorded this
correlation of Hcy level with left atrial diameter
increases, p = 0.001
A significant correlation was found between Hcy levels and left atrial diameter (r = 0.46; P <.001)
PMID 15389232 · one of two readings recorded this
ischemic complications during NVAF
increases
elevated Hcy levels were an independent risk factor for ischemic complications during NVAF (OR 2.66, 95% CI 1.15-6.20)
PMID 15389232 · one of two readings recorded this
nonvalvular atrial fibrillation
increases
Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46
PMID 15389232 · one of two readings recorded this
nonvalvular atrial fibrillation
increases
vitamin B6: OR 3.02, 95% CI 1.02-8.95
PMID 15389232 · one of two readings recorded this
presence of nonvalvular atrial fibrillation in patients on oral anticoagulants versus controls, by plasma vitamin B6 quartile (case-control, not incident AF)
increases, vitamin B6 deficiency (lowest quartile) OR 3.02, 95% CI 1.02-8.95
Not recorded as a finding: this platform holds no node for the endpoint
Hyperhomocysteinemia (highest quartile) and vitamin B6 deficiency (lowest quartile) were independently associated with NVAF after multivariate analysis (Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46; vitamin B6: OR 3.02, 95% CI 1.02-8.95).
PMID 15389232 · one of two readings recorded this
presence of nonvalvular atrial fibrillation in patients versus controls by plasma vitamin B6 status (lowest quartile)
increases, vitamin B6 deficiency OR 3.02, 95% CI 1.02-8.95
Not recorded as a finding: this platform holds no node for the endpoint
Hyperhomocysteinemia (highest quartile) and vitamin B6 deficiency (lowest quartile) were independently associated with NVAF after multivariate analysis (Hcy: odds ratio [OR] 6.40, 95% CI 3.29-12.46; vitamin B6: OR 3.02, 95% CI 1.02-8.95).
PMID 15389232 · one of two readings recorded this
acute neuroleptic-induced akathisia severity, Barnes Akathisia Scale (BAS) subscales
increases, at least 2-point BAS global reduction in 8 patients (80%) with vitamin B6 vs 3 (30%) placebo, p = 0.037
Not recorded as a finding: this platform holds no node for the endpoint
A reduction of at least 2 points on the BAS global subscale was noted in 8 patients in the vitamin B6 group (80%), and in only 3 patients in the placebo group (30%) (p = .037).
PMID 15554771 · one of two readings recorded this
Barnes Akathisia Scale global subscale
decreases, p = 0.004, n = 20
The vitamin B6-treated patients in comparison with the placebo group showed a significant improvement on the subjective-awareness of restlessness (p = .0004), subjective-distress (p = .01), and global (p = .004) subscales of the BAS
PMID 15554771 · one of two readings recorded this
Barnes Akathisia Scale objective subscale
no effect, p = 0.079, n = 20
The objective subscale did not demonstrate significant positive results (p = .079)
PMID 15554771 · one of two readings recorded this
Barnes Akathisia Scale subjective-awareness of restlessness subscale
decreases, p = 0.0004, n = 20
The vitamin B6-treated patients in comparison with the placebo group showed a significant improvement on the subjective-awareness of restlessness (p = .0004), subjective-distress (p = .01), and global (p = .004) subscales of the BAS
PMID 15554771 · one of two readings recorded this
Barnes Akathisia Scale subjective-distress subscale
decreases, p = 0.01, n = 20
The vitamin B6-treated patients in comparison with the placebo group showed a significant improvement on the subjective-awareness of restlessness (p = .0004), subjective-distress (p = .01), and global (p = .004) subscales of the BAS
PMID 15554771 · one of two readings recorded this
responders, reduction of at least 2 points on BAS global subscale
p = 0.037, n = 20
A reduction of at least 2 points on the BAS global subscale was noted in 8 patients in the vitamin B6 group (80%), and in only 3 patients in the placebo group (30%) (p = .037)
PMID 15554771 · one of two readings recorded this
responders, reduction of at least 2 points on BAS global subscale
decreases, p = 0.037, n = 20
A reduction of at least 2 points on the BAS global subscale was noted in 8 patients in the vitamin B6 group (80%), and in only 3 patients in the placebo group (30%) (p = .037)
PMID 15554771 · one of two readings recorded this
albumin concentration, mean change from baseline vs placebo
decreases
The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)
PMID 15671107 · one of two readings recorded this
albumin concentration, mean change from baseline vs placebo
decreases
The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)
PMID 15671107 · one of two readings recorded this
methionine-homocysteine flux rates (transmethylation, remethylation, transsulfuration)
no effect
No significant changes in flux rates were observed
PMID 15671107 · one of two readings recorded this
plasma homocysteine concentration, mean change from baseline vs placebo
decreases
The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)
PMID 15671107 · one of two readings recorded this
plasma homocysteine concentration, mean change from baseline vs placebo
decreases
The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)
PMID 15671107 · one of two readings recorded this
plasma vitamin B6 concentration after oral estradiol in postmenopausal women
decreases, vitamin B6 decreased 25% with estradiol and 38% with estradiol plus dydrogesterone
Not recorded as a finding: the compound is what was measured, not what was given
The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%).
PMID 15671107 · one of two readings recorded this
vitamin B6 concentration, mean change from baseline vs placebo
decreases
The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)
PMID 15671107 · one of two readings recorded this
vitamin B6 concentration, mean change from baseline vs placebo
decreases
The mean change from baseline in homocysteine concentration by both treatments compared with placebo (ET, -13%; EPT, -10%) was accompanied by a decrease in the concentration of vitamin B6 (ET, -25%; EPT, -38%) and albumin (ET, -7%; EPT, -11%)
PMID 15671107 · one of two readings recorded this
advanced distal colorectal adenoma risk
decreases, p = 0.08
RR = 0.65, 95% CI = 0.37 to 1.11; P(trend) = .08
PMID 15870439 · one of two readings recorded this
colon cancer risk
decreases, p = 0.02
RR = 0.42, 95% CI = 0.21 to 0.85; P(trend) = .02
PMID 15870439 · one of two readings recorded this
colon cancer risk
decreases, p = 0.01
for colon cancer, RR = 0.38, 95% CI = 0.18 to 0.80; P(trend) = .01
PMID 15870439 · one of two readings recorded this
colon cancer risk
decreases, p = 0.007
RR = 0.51, 95% CI = 0.27 to 0.97; P(trend) = .007
PMID 15870439 · one of two readings recorded this
colorectal cancer risk
decreases, p = 0.07
RR = 0.56, 95% CI = 0.31 to 1.01; P(trend) = .07
PMID 15870439 · one of two readings recorded this
colorectal cancer risk
decreases, p = 0.03
for colorectal cancer, RR = 0.48, 95% CI = 0.25 to 0.92; P(trend) = .03
PMID 15870439 · one of two readings recorded this
early-stage colorectal adenoma risk
no effect, p = 0.52
RR = 0.85, 95% CI = 0.52 to 1.38; P(trend) = .52
PMID 15870439 · one of two readings recorded this
plasma pyridoxal 5'-phosphate concentration and total vitamin B6 intake in relation to colon cancer risk, nested case-control, Nurses' Health Study
decreases, RR = 0.51, 95% CI = 0.27 to 0.97; P(trend) = .007
Not recorded as a finding: a node exists but the paper states a different instrument or population
Total vitamin B(6) intake was also statistically significantly inversely associated with colon cancer risk (RR = 0.51, 95% CI = 0.27 to 0.97; P(trend) = .007).
PMID 15870439 · one of two readings recorded this
risk of colon cancer by total vitamin B6 intake; colorectal cancer and adenoma by plasma pyridoxal 5'-phosphate quartile, nested case-control
decreases, RR = 0.51, 95% CI = 0.27 to 0.97 for total vitamin B6 intake and colon cancer
Not recorded as a finding: a node exists but the paper states a different instrument or population
Total vitamin B(6) intake was also statistically significantly inversely associated with colon cancer risk (RR = 0.51, 95% CI = 0.27 to 0.97; P(trend) = .007).
PMID 15870439 · one of two readings recorded this
colorectal cancer risk, trend across vitamin B6 intake
decreases, p = 0.002
long-term intake of dietary vitamin B6 was significantly inversely associated with risk of colorectal cancer (P value for trend = .002)
PMID 15940618 · one of two readings recorded this
colorectal cancer risk
decreases
those in the highest quintile had a 34% lower risk (multivariate rate ratio, 0.66; 95% confidence interval, 0.50-0.86)
PMID 15940618 · one of two readings recorded this
colorectal cancer risk
decreases
The multivariate rate ratio of colorectal cancer comparing extreme quintiles of vitamin B6 intake was 0.28 (95% confidence interval, 0.13-0.59) among women who consumed > or = 30 g/wk of alcohol
PMID 15940618 · one of two readings recorded this
adequacy of thiamin status
unclear
Although B1 intake of greater than or equal to 1.0 mg/day was adequate for maintenance of normal thiamin status in most subjects of this study
PMID 1619179 · one of two readings recorded this
EALT indices sensitivity to B6 intake versus EAST indices
unclear
Although the EALT-indices were more sensitive to changes in B6 intake than the EAST-indices, the EASTBA and SA correlated most consistently with the intake
PMID 1619179 · one of two readings recorded this
erythrocyte alanine and aspartate aminotransferase apoenzyme levels
decreases
Both alanine (EALT) and aspartate (EAST) aminotransferase apoenzyme levels declined and AC values increased significantly during the first 3 months
PMID 1619179 · one of two readings recorded this
erythrocyte aminotransferase activity coefficients
increases
Both alanine (EALT) and aspartate (EAST) aminotransferase apoenzyme levels declined and AC values increased significantly during the first 3 months
PMID 1619179 · one of two readings recorded this
erythrocyte transketolase activities and activity coefficients correlation with B1 intake
unclear
Postoperative erythrocyte transketolase basal (BA) and thiamin pyrophosphate-stimulated (SA) activities and activity coefficients (AC) correlated significantly with B1 intake
PMID 1619179 · one of two readings recorded this
maintenance of coenzyme saturation of erythrocyte aminotransferases
no effect
Vitamin B6 intake at the current recommended dietary allowance (1.6 mg) was not adequate to maintain coenzyme saturation of the erythrocyte aminotransferases
PMID 1619179 · one of two readings recorded this
24 h urinary xanthurenic acid (XA) excretion after tryptophan load
modulates
Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion
PMID 16277693 · one of two readings recorded this
Erythrocyte aspartate aminotransferase activity coefficient (alphaEAST)
modulates
Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion
PMID 16277693 · one of two readings recorded this
Erythrocyte pyridoxal 5'-phosphate concentration
increases
Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion
PMID 16277693 · one of two readings recorded this
plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte aspartate aminotransferase activity coefficient (alphaEAST), urinary 4-pyridoxic acid and xanthurenic acid excretion; TNF-alpha and IL-6 production
increases
Not recorded as a finding: this platform holds no node for the endpoint
Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion.
PMID 16277693 · one of two readings recorded this
Plasma pyridoxal 5'-phosphate concentration
increases
Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion
PMID 16277693 · one of two readings recorded this
Post-methionine load net homocysteine increase (DeltatHcy)
decreases, p = 0.09
Pyridoxine supplementation also showed a trend (p < 0.09) towards a reduction in post-methionine load DeltatHcy
PMID 16277693 · one of two readings recorded this
Pro-inflammatory cytokine production (TNF-alpha, IL-6)
no effect
Supplementation did not affect pro-inflammatory cytokine production
PMID 16277693 · one of two readings recorded this
pro-inflammatory cytokine (TNF-alpha and IL-6) production before and after 50 mg/day pyridoxine for 30 days vs placebo in rheumatoid arthritis; CRP and ESR also examined but no result stated in the abstract
no effect, supplementation did not affect pro-inflammatory cytokine production
Not recorded as a finding: a node exists but the paper states a different instrument or population
Supplementation did not affect pro-inflammatory cytokine production.
PMID 16277693 · one of two readings recorded this
Urinary 4-pyridoxic acid (4-PA) excretion
increases
Pyridoxine supplementation significantly improved plasma and erythrocyte pyridoxal 5'-phosphate concentrations, erythrocyte alphaEAST, urinary 4-PA, and XA excretion
PMID 16277693 · one of two readings recorded this
Colorectal cancer risk, dietary folate and vitamin B6 intake
decreases
dietary intakes of folate and vitamin B(6) were significantly inversely associated with colorectal cancer risk among women who were not taking supplements containing folate and vitamin B(6)
PMID 16339055 · one of two readings recorded this
Colorectal cancer risk, dietary folate intake
decreases
0.46 (95% CI: 0.26, 0.81) for dietary folate
PMID 16339055 · one of two readings recorded this
Colorectal cancer risk, dietary vitamin B6 intake
no effect
0.69 (95% CI: 0.41, 1.15) for dietary vitamin B(6)
PMID 16339055 · one of two readings recorded this
Colorectal cancer risk, multivitamin supplement use
no effect
The use of multivitamin supplements was not related to colorectal cancer risk
PMID 16339055 · one of two readings recorded this
Colorectal cancer risk, total folate intake
no effect
1.16 (95% confidence interval (CI): 0.76, 1.79) for total folate
PMID 16339055 · one of two readings recorded this
Colorectal cancer risk, total vitamin B6 intake
no effect
1.14 (95% CI: 0.77, 1.69) for total vitamin B(6)
PMID 16339055 · one of two readings recorded this
colorectal cancer risk
unclear
Although folate intake was inversely associated with colorectal cancer, this association was attenuated after further controlling for dietary fiber intake
PMID 16351505 · one of two readings recorded this
colorectal cancer risk
no effect
Neither vitamin B6, vitamin B12, nor vitamin B2, nor any genetic polymorphism was significantly associated with colorectal cancer
PMID 16351505 · one of two readings recorded this
colorectal cancer risk
no effect
Neither vitamin B6, vitamin B12, nor vitamin B2, nor any genetic polymorphism was significantly associated with colorectal cancer
PMID 16351505 · one of two readings recorded this
colorectal cancer risk
no effect
Neither vitamin B6, vitamin B12, nor vitamin B2, nor any genetic polymorphism was significantly associated with colorectal cancer
PMID 16351505 · one of two readings recorded this
blood folic acid
decreases
Patients receiving phenytoin had significantly lower folic acid levels
PMID 16414291 · one of two readings recorded this
blood homocysteine
no effect
No difference in homocysteine concentrations was observed among epileptic patients in terms of the anti-epileptic drug used
PMID 16414291 · one of two readings recorded this
blood homocysteine
increases
Compared to the control group, epileptic patients on anti-epileptic drug had higher blood levels of homocysteine
PMID 16414291 · one of two readings recorded this
blood homocysteine
no effect
Because there was no significant change in homocysteine concentrations in epileptic patients who were not receiving an anti-epileptic drug
PMID 16414291 · one of two readings recorded this
blood pyridoxal 5'-phosphate (active circulating form of vitamin B6) in epileptic patients on anti-epileptic drugs versus other patients
decreases
Not recorded as a finding: the compound is what was measured, not what was given
Patients receiving phenytoin had significantly lower folic acid levels and those receiving carbamazepine had marginally lower pyridoxal 5'-phosphate levels in comparison with those using other anti-epileptic drugs.
PMID 16414291 · one of two readings recorded this
blood pyridoxal 5'-phosphate
decreases
those receiving carbamazepine had marginally lower pyridoxal 5'-phosphate levels in comparison with those using other anti-epileptic drugs
PMID 16414291 · one of two readings recorded this
correlation of homocysteine with folic acid concentration
decreases
A negative correlation between homocysteine and folic acid concentrations was detected in epileptic patients on anti-epileptic drug
PMID 16414291 · one of two readings recorded this
folic acid level versus duration of anti-epileptic drug use
decreases
The duration of anti-epileptic drug use was correlated to the decrease of folic acid levels, but not with changes observed in homocysteine, Vitamin B12 and pyridoxal 5'-phosphate levels
PMID 16414291 · one of two readings recorded this
homocysteine level versus seizure frequency
no effect
No relationship between seizure frequency and homocysteine levels was observed in epileptic patients
PMID 16414291 · one of two readings recorded this
pyridoxal 5'-phosphate level versus duration of anti-epileptic drug use
no effect
The duration of anti-epileptic drug use was correlated to the decrease of folic acid levels, but not with changes observed in homocysteine, Vitamin B12 and pyridoxal 5'-phosphate levels
PMID 16414291 · one of two readings recorded this
acute neuroleptic-induced akathisia severity, Barnes Akathisia Rating Scale global subscale
increases, at least 2-point BARS global reduction in 13/23 (56%) with vitamin B6 vs 1/17 (6%) placebo
Not recorded as a finding: this platform holds no node for the endpoint
A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005).
PMID 16614537 · one of two readings recorded this
Barnes Akathisia Rating Scale global subscale
decreases, p = 0.0001
Compared with the placebo group, the vitamin B(6)-treated and mianserin-treated patients showed a significant improvement in the subjective (P < 0.0001), subjective distress (P < 0.0001), and global (P < 0.0001) subscales
PMID 16614537 · one of two readings recorded this
Barnes Akathisia Rating Scale objective subscale
no effect, p = 0.056
The objective subscale did not show significant positive results (P = 0.056)
PMID 16614537 · one of two readings recorded this
Barnes Akathisia Rating Scale subjective distress subscale
decreases, p = 0.0001
Compared with the placebo group, the vitamin B(6)-treated and mianserin-treated patients showed a significant improvement in the subjective (P < 0.0001), subjective distress (P < 0.0001), and global (P < 0.0001) subscales
PMID 16614537 · one of two readings recorded this
Barnes Akathisia Rating Scale subjective subscale
decreases, p = 0.0001
Compared with the placebo group, the vitamin B(6)-treated and mianserin-treated patients showed a significant improvement in the subjective (P < 0.0001), subjective distress (P < 0.0001), and global (P < 0.0001) subscales
PMID 16614537 · one of two readings recorded this
responders, reduction of at least 2 points on Barnes Akathisia Rating Scale global subscale
decreases, p = 0.0005, n = 20
A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005)
PMID 16614537 · one of two readings recorded this
responders, reduction of at least 2 points on Barnes Akathisia Rating Scale global subscale
p = 0.0005, n = 17
A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005)
PMID 16614537 · one of two readings recorded this
responders, reduction of at least 2 points on Barnes Akathisia Rating Scale global subscale
decreases, p = 0.0005, n = 23
A reduction of at least 2 points on the Barnes Akathisia Rating Scale global subscale was noted in the vitamin B(6) group (13/23, 56%) as well as in the mianserin groups (13/20, 65%), and in only one patient in the placebo group (1/17, 6%; P < 0.0005)
PMID 16614537 · one of two readings recorded this
Apgar scores and breastmilk production
no effect, n = 24
between controls and women receiving oral (n = 24; one trial) or intramuscular (n = 24; one trial) loading doses of pyridoxine at labour
PMID 16625530 · one of two readings recorded this
Apgar scores and breastmilk production
no effect, n = 24
between controls and women receiving oral (n = 24; one trial) or intramuscular (n = 24; one trial) loading doses of pyridoxine at labour
PMID 16625530 · one of two readings recorded this
Apgar scores at one and five minutes after oral or intramuscular loading dose of pyridoxine at labour
no effect
Not recorded as a finding: no_outcome_node: no node for Apgar score
No differences were found in Apgar scores at one or five minutes, or breastmilk production between controls and women receiving oral (n = 24; one trial) or intramuscular (n = 24; one trial) loading doses of pyridoxine at labour.
PMID 16625530 · one of two readings recorded this
dental decay in pregnant women, vitamin B6 capsules or lozenges
decreases, capsules RR 0.84, 95% CI 0.71 to 0.98; lozenges RR 0.68, 95% CI 0.56 to 0.83
Not recorded as a finding: no_outcome_node: no node for dental decay
Vitamin B6 as oral capsules or lozenges resulted in decreased risk of dental decay in pregnant women (capsules: relative risk (RR) 0.84; 95% confidence interval (CI) 0.71 to 0.98; one trial, n = 371; lozenges: RR 0.68; 95% CI 0.56 to 0.83; one trial, n = 342).
PMID 16625530 · one of two readings recorded this
dental decay risk in pregnant women, incidence of decay (capsules and lozenges)
decreases, capsules RR 0.84, 95% CI 0.71 to 0.98; lozenges RR 0.68, 95% CI 0.56 to 0.83
Not recorded as a finding: no_outcome_node: dental caries incidence has no entry in the outcome list
Vitamin B6 as oral capsules or lozenges resulted in decreased risk of dental decay in pregnant women (capsules: relative risk (RR) 0.84; 95% confidence interval (CI) 0.71 to 0.98; one trial, n = 371; lozenges: RR 0.68; 95% CI 0.56 to 0.83; one trial, n = 342).
PMID 16625530 · one of two readings recorded this
dental decay risk
decreases, n = 342
lozenges: RR 0.68; 95% CI 0.56 to 0.83; one trial, n = 342
PMID 16625530 · one of two readings recorded this
dental decay risk
decreases, n = 371
capsules: relative risk (RR) 0.84; 95% confidence interval (CI) 0.71 to 0.98; one trial, n = 371
PMID 16625530 · one of two readings recorded this
eclampsia risk
no effect, n = 1242
We did not find any statistically significant differences in the risk of eclampsia (capsules: n = 1242; three trials; lozenges: n = 944; one trial)
PMID 16625530 · one of two readings recorded this
eclampsia risk
no effect, n = 944
We did not find any statistically significant differences in the risk of eclampsia (capsules: n = 1242; three trials; lozenges: n = 944; one trial)
PMID 16625530 · one of two readings recorded this
low Apgar score at one minute
no effect, n = 45
low Apgar scores at one minute (oral pyridoxine: n = 45; one trial)
PMID 16625530 · one of two readings recorded this
mean birthweight
decreases, n = 33
A small trial showed reduced mean birthweights with vitamin B6 supplementation (weighted mean difference -0.23 kg; 95% CI -0.42 to -0.04; n = 33; one trial)
PMID 16625530 · one of two readings recorded this
pre-eclampsia risk
no effect, n = 1197
pre-eclampsia (capsules n = 1197; two trials; lozenges: n = 944; one trial)
PMID 16625530 · one of two readings recorded this
pre-eclampsia risk
no effect, n = 944
pre-eclampsia (capsules n = 1197; two trials; lozenges: n = 944; one trial)
PMID 16625530 · one of two readings recorded this
immune responses (white blood cell, neutrophils, lymphocyte subsets)
no effect
There were no significant changes with respect to immune responses in the control group over 14 days
PMID 16670691 · one of two readings recorded this
plasma 4-pyridoxic acid (4-PA)
increases
Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups
PMID 16670691 · one of two readings recorded this
plasma pyridoxal 5'-phosphate (PLP)
increases
Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups
PMID 16670691 · one of two readings recorded this
plasma pyridoxal (PL)
increases
Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups
PMID 16670691 · one of two readings recorded this
T-helper (CD4) cell number
increases
Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day
PMID 16670691 · one of two readings recorded this
T-helper (CD4) cell number
increases
T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6 -50 group
PMID 16670691 · one of two readings recorded this
T-lymphocyte (CD3) number
increases
T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6 -50 group
PMID 16670691 · one of two readings recorded this
T-lymphocyte (CD3), T-helper (CD4) and T-suppressor (CD8) cell numbers and percentages, total lymphocyte count in ICU patients
increases, significant increase on day 14 within the B6-50 group
Not recorded as a finding: the result compares a group with itself, not with a control
T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6 -50 group.
PMID 16670691 · one of two readings recorded this
T-lymphocyte percentage
increases
Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day
PMID 16670691 · one of two readings recorded this
T-suppressor (CD8) cell number
increases
Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day
PMID 16670691 · one of two readings recorded this
T-suppressor (CD8) cell percentage
increases
Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day
PMID 16670691 · one of two readings recorded this
T-suppressor (CD8) cell percentage
increases
T-lymphocyte and T-helper cell numbers and the percentage of T-suppressor cell significantly increased on day 14 in the B6 -50 group
PMID 16670691 · one of two readings recorded this
total lymphocyte count (TLC)
increases
Total lymphocyte count, T-helper and T-suppressor cell numbers, the percentage of T-lymphocyte cells and T-suppressors significantly increased in the B6 -100 group at the 14th day
PMID 16670691 · one of two readings recorded this
urinary 4-pyridoxic acid (4-PA)
increases
Plasma PLP, PL, 4-PA and urinary 4-PA concentrations significantly increased in two treated groups
PMID 16670691 · one of two readings recorded this
flow-mediated dilation, brachial artery
increases, n = 35
This improvement in flow-mediated dilation occurred within 2 hours and was maintained at 8 weeks for each treatment
PMID 16818571 · one of two readings recorded this
flow-mediated dilation, brachial artery
increases
and with folate/vitamin B6 from 2.8% +/- 3.5% to 10.5% +/- 4.4%
PMID 16818571 · one of two readings recorded this
flow-mediated dilation, brachial artery
increases
flow-mediated dilation improved with folate from 2.6% +/- 4.3% (mean +/- SD) to 9.7% +/- 6.0%
PMID 16818571 · one of two readings recorded this
flow-mediated dilation, brachial artery
no effect
Flow-mediated dilation in the placebo group, and glyceryltrinitrate-induced dilation in all groups, did not change
PMID 16818571 · one of two readings recorded this
flow-mediated dilation, brachial artery
increases
with vitamin B6 from 3.5% +/- 4.0% to 8.3% +/- 4.2%
PMID 16818571 · one of two readings recorded this
glyceryltrinitrate-induced dilation, brachial artery
no effect
Flow-mediated dilation in the placebo group, and glyceryltrinitrate-induced dilation in all groups, did not change
PMID 16818571 · one of two readings recorded this
incident Parkinson disease
no effect
No association was observed for dietary folate and vitamin B(12)
PMID 16864826 · one of two readings recorded this
incident Parkinson disease
no effect
No association was observed for dietary folate and vitamin B(12)
PMID 16864826 · one of two readings recorded this
incident Parkinson disease
decreases
for highest vs lowest tertile, 0.46 [0.22 to 0.96]
PMID 16864826 · one of two readings recorded this
incident Parkinson disease
decreases
hazard ratio per SD, 0.69 [95% CI 0.50 to 0.96]
PMID 16864826 · one of two readings recorded this
incident Parkinson disease
decreases
Stratified analyses showed that this association was restricted to smokers
PMID 16864826 · one of two readings recorded this
incident exocrine pancreatic cancer cases
n = 81922
During a mean follow-up of 7.2 years, through June 2005, 147 incident cases of pancreatic cancer were diagnosed
PMID 17241865 · one of two readings recorded this
pancreatic cancer incidence, dietary or total vitamin B6 intake
no effect
whereas no significant association was observed for dietary or total vitamin B(6) intake
PMID 17241865 · one of two readings recorded this
pancreatic cancer incidence, methionine intake highest vs lowest quartile
decreases, p = 0.0005
were 0.44 (95% CI, 0.26-0.73; P for trend = .0005) in women and men combined
PMID 17241865 · one of two readings recorded this
pancreatic cancer incidence, methionine intake highest vs lowest quartile
decreases, p = 0.002
0.32 (95% CI, 0.15-0.65; P for trend = .002) in men
PMID 17241865 · one of two readings recorded this
pancreatic cancer incidence, methionine intake highest vs lowest quartile
no effect, p = 0.07
0.59 (95% CI, 0.28-1.21; P for trend = .07) in women
PMID 17241865 · one of two readings recorded this